The use of biomarkers to target treatment improves patient outcomes by making earlier and more appropriate treatment selections, and the number of markers has increased dramatically in the past decade.  Breast cancer was highly segmented even in the early 2000s, but the addition of the BRCA 1/2 genetic marker further isolates responders to specific treatments.